Shock management: Part II. Pharmacologic intervention.
D004837:Epinephrine / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008680:Metaraminol / Q000494:pharmacology; D008729:Methoxamine / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects; D005996:Nitroglycerin / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000502:physiology; D011954:Receptors, Dopamine / Q000502:physiology; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology
D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D009599:Nitroprusside; D010656:Phenylephrine; D009020:Morphine; D008680:Metaraminol; D005996:Nitroglycerin; D008729:Methoxamine; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine